DK0738273T3 - Monohydrate of (E) - 2 '- (fluoromethylene) - cytidine - Google Patents

Monohydrate of (E) - 2 '- (fluoromethylene) - cytidine

Info

Publication number
DK0738273T3
DK0738273T3 DK95907232T DK95907232T DK0738273T3 DK 0738273 T3 DK0738273 T3 DK 0738273T3 DK 95907232 T DK95907232 T DK 95907232T DK 95907232 T DK95907232 T DK 95907232T DK 0738273 T3 DK0738273 T3 DK 0738273T3
Authority
DK
Denmark
Prior art keywords
fluoromethylene
cytidine
monohydrate
deoxy
neoplastic
Prior art date
Application number
DK95907232T
Other languages
Danish (da)
Inventor
Richard E Donaldson
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of DK0738273T3 publication Critical patent/DK0738273T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to the novel monohydrate or (E)-2'-deoxy-2'-(fluoromethylene)cytidine useful as a ribonucleotide reductase inhibitor in the treatment of patients afflicted with neoplastic or viral disease states.
DK95907232T 1994-01-07 1994-12-13 Monohydrate of (E) - 2 '- (fluoromethylene) - cytidine DK0738273T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17895294A 1994-01-07 1994-01-07
PCT/US1994/014648 WO1995018815A1 (en) 1994-01-07 1994-12-13 Monohydrate of (e)-2'-deoxy-2'-(fluoromethylene)cytidine

Publications (1)

Publication Number Publication Date
DK0738273T3 true DK0738273T3 (en) 2000-04-17

Family

ID=22654587

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95907232T DK0738273T3 (en) 1994-01-07 1994-12-13 Monohydrate of (E) - 2 '- (fluoromethylene) - cytidine

Country Status (20)

Country Link
EP (1) EP0738273B1 (en)
JP (1) JPH09511227A (en)
KR (1) KR100330328B1 (en)
CN (1) CN1043231C (en)
AT (1) ATE186732T1 (en)
AU (1) AU684604B2 (en)
CA (1) CA2179987C (en)
DE (1) DE69421721T2 (en)
DK (1) DK0738273T3 (en)
ES (1) ES2141330T3 (en)
FI (1) FI114396B (en)
GR (1) GR3032614T3 (en)
HU (1) HU217849B (en)
IL (1) IL112242A (en)
MX (1) MX9500363A (en)
NO (1) NO306409B1 (en)
NZ (1) NZ279030A (en)
TW (1) TW397838B (en)
WO (1) WO1995018815A1 (en)
ZA (1) ZA9512B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309350C (en) 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Purine derivatives and medicaments comprising the same as active ingredient
EP1178046B1 (en) 1999-05-11 2003-11-19 Mitsubishi Chemical Corporation Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002648C (en) * 1988-11-15 2000-02-29 James R. Mccarthy 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
FI95269C (en) * 1989-05-15 1996-01-10 Squibb Bristol Myers Co Antiviral, highly water-soluble, stable, crystalline salts of 2 ', 3'-dideoxyinosine monohydrate, 2', 3'-dideoxy-2 ', 3'-didehydrotymidine monohydrate and 2', 3'-dideoxy-2'-fluorinosine hemihydrate
JPH0615557B2 (en) * 1990-02-19 1994-03-02 ヤマサ醤油株式会社 2'-deoxy-2'-methylidene cytidine dihydrate crystal
DE69306570T2 (en) * 1992-05-12 1997-04-10 Merrell Pharmaceuticals Inc N METHOD FOR PRODUCING RIBONUCLEOTIDE REDUCTASE INHIBITORS

Also Published As

Publication number Publication date
IL112242A0 (en) 1995-03-30
CN1141045A (en) 1997-01-22
NO306409B1 (en) 1999-11-01
HUT75055A (en) 1997-03-28
TW397838B (en) 2000-07-11
GR3032614T3 (en) 2000-05-31
AU684604B2 (en) 1997-12-18
CN1043231C (en) 1999-05-05
EP0738273A1 (en) 1996-10-23
MX9500363A (en) 1998-04-30
NO962848L (en) 1996-09-06
KR100330328B1 (en) 2002-12-05
CA2179987A1 (en) 1995-07-13
FI114396B (en) 2004-10-15
NZ279030A (en) 1997-05-26
HU217849B (en) 2000-04-28
DE69421721T2 (en) 2000-04-27
FI962769A (en) 1996-07-05
ES2141330T3 (en) 2000-03-16
AU1553295A (en) 1995-08-01
ZA9512B (en) 1995-09-11
EP0738273B1 (en) 1999-11-17
JPH09511227A (en) 1997-11-11
DE69421721D1 (en) 1999-12-23
IL112242A (en) 2000-08-31
FI962769A0 (en) 1996-07-05
CA2179987C (en) 1999-01-19
WO1995018815A1 (en) 1995-07-13
NO962848D0 (en) 1996-07-05
HU9601848D0 (en) 1996-09-30
ATE186732T1 (en) 1999-12-15

Similar Documents

Publication Publication Date Title
DK480284A (en) TRUCKMARKED CONJUGATES OF METALLOTHIONEIN AND TARGETING, BIOLOGICAL ACTIVE MOLECULES
BRPI0411900A (en) antiviral compounds and methods
TR199701212T1 (en) Use of alpha IL-agonists for the treatment of urinary incontinence.
DK1021410T3 (en) Prostaglandin agonists and their use in the treatment of bone conditions
DE60208794D1 (en) 4'-SUBSTITUTED NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS C-VIRUS-MEDIATED ILLNESSES
BR9506667A (en) Process chlorine-pyrimidine intermediate compound for the preparation of the process chlorine-pyrimidine intermediate compound for the preparation of 2,5-diamino-4,6-dichloro-pyrimidine process for the preparation of 2,6-diamino-purines and process for the preparation of (1s, 4s) -4-2-amino-6- (cyclo-propyl-amino) -9h-purin-9-yl¾-2-cyclo-pentene-1-methanol
ES2190447T3 (en) DISPOSABLE DIAPER.
DK0755249T3 (en) Use of Maillard reaction inhibitor to treat amyloidosis-based disease
ES2191292T3 (en) POLYAROMATIC ANTIVIRAL COMPOUNDS.
CA2002648A1 (en) 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
DK0983271T3 (en) Carbocyclic nucleoside hemisulfate and its use in the treatment of viral infections
DK0750616T3 (en) Acid addition salts of 2,3,4,5-tetrahydro-1H-3-benzazapine compounds
DK0738273T3 (en) Monohydrate of (E) - 2 '- (fluoromethylene) - cytidine
DK0625158T3 (en) Therapeutic nucleosides of the 2 ', 3'-dideoxy-3'-fluoropurine series
DK0550532T3 (en) Dextrin sulfates as anti-HIV-1 agents and preparations containing them
ATE493951T1 (en) CORTICAL BONE IMPLANT FOR SMITH-ROBINSON VERTERAL FUSION
ZA991641B (en) Treatment of viral disease in swine.
DK0459176T3 (en) Oligophosphates with antiviral action
BR0012380A (en) 2-amino-benzoxazinones for the treatment of herpes simplex virus
DE69407180T2 (en) FLUORO NUCLEOSIDE CLEANING
ES2181160T3 (en) DERIVATIVES OF 1,4-DIHYDROPIRIDINE AND ITS USE IN THERAPY.
BR9804966A (en) Toy, base panel and piece
ITCA950008A0 (en) USE OF COMBINATIONS OF NUCLEOSIDE ANALOGUES IN THE THERAPY OF AIDS INFECTIONS.